SMARCA1 and lung adenocarcinoma: However, there are a variety of cancer types in which the genetic alterations of the SWI/SNF complex tended to have copy number variations, particularly amplifications, such as in lung squamous cell carcinoma (61.06%), ovarian cancer (58.71%), sarcoma (47.89%), esophageal cancer (40.32%), cervical cancer (35.48%), head and neck cancer (32.45%), breast cancer (32.13%), bladder cancer (33.41%), lung adenocarcinoma (31.39%), stomach cancer (29.70%), uterine cancer (26.28%), glioma (23.87%), liver cancer (23.08%) and prostate cancer (22.58%) (Fig 2A).